Dimensional Fund Advisors
ORMP icon

Dimensional Fund Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Dimensional Fund Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$974K Buy
202,609
+44,400
+28% +$177K ﹤0.01% 2869
2026
Q1 		$538K Buy
158,209
+7,738
+5% +$26.3K ﹤0.01% 2931
2025
Q4 		$429K Buy
150,471
+2,984
+2% +$7.7K ﹤0.01% 2993
2025
Q3 		$389K Sell
147,487
-19,412
-12% -$42.9K ﹤0.01% 3033
2025
Q2 		$376K Buy
166,899
+25,818
+18% +$56.9K ﹤0.01% 3039
2025
Q1 		$302K Buy
141,081
+22,086
+19% +$51K ﹤0.01% 3078
2024
Q4 		$288K Buy
118,995
+70,190
+144% +$167K ﹤0.01% 3120
2024
Q3 		$119K Buy
48,805
+17,335
+55% +$42.3K ﹤0.01% 3225
2024
Q2 		$80.9K Buy
31,470
+10,774
+52% +$25.6K ﹤0.01% 3272
2024
Q1 		$60.4K Buy
+20,696
New +$57.9K ﹤0.01% 3320
2023
Q4 		– Sell
-27,285
Closed -$71.2K – 3444
2023
Q3 		$71.2K Buy
+27,285
New +$85.9K ﹤0.01% 3351

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors's ORMP Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Oramed Pharmaceuticals (ORMP) stake by 28% in Q2 2026, buying an estimated $177K and bringing the position to 202,609 shares worth $974K. The position accounts for ﹤0.01% of the portfolio, ranked #2869.

Dimensional Fund Advisors first reported a position in ORMP in Q3 2023 and has held it in 11 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Dimensional Fund Advisors held 202,609 shares of Oramed Pharmaceuticals worth $974K as of Q2 2026.
  • Dimensional Fund Advisors bought 44,400 Oramed Pharmaceuticals shares in Q2 2026, an estimated $177K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2869 holding.
  • Dimensional Fund Advisors first reported a position in Oramed Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.